Novel Mithramycin Derivatives for Cancer Chemotherapy (2198)
- Technology Benefits
- Key Advantages • Improved selectivity for betterefficacy and fewer off-target effects• Potential for less toxicity thanavailable chemotherapeutic agents currently in the clinic• Better pharmacological propertiesthan current chemotherapies in use today
- Detailed Technology Description
- The University of Kentucky is seeking a partner to further develop and commercializevarious mithramycin SA derivatives that were synthesized from a mithramycinSA-producing mutant. The derivatives of particular interest are thosecontaining the dipeptides L-Phe and L-Trp, and provide the potential for moreefficacious and less toxic chemotherapeutic interventions for Ewing’s Sarcoma.
- *Abstract
-
- Country/Region
- USA
For more information, please click Here
